関連する実験動画
Updated: Sep 9, 2025

09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
12.1K
頭蓋内出血後に抗凝固剤を再開するタイミング
Sejin Choi1, Myoung-Jin Jang2, Kangmin Kim1
1Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Journal of Korean Neurosurgical Society
|September 1, 2025
まとめ
自発的頭蓋内出血 (sICH) の約3週間後に抗凝固剤を再開することは,リスクを最小限に抑えるのに最適である. このタイミングは,抗凝固剤治療の患者の再出血の危険に対する脳卒中予防の必要性をバランスします.
科学分野:
- 神経学
- 心臓病科
- 薬理学について
背景:
- 抗凝固剤療法を受けている患者にとって,自発性頭蓋内出血 (sICH) は重大なリスクをもたらす.
- 血栓塞栓と出血のリスクのバランスをとるには,sICH後に抗凝固剤を再開する最適なタイミングを決定することが重要です.
研究 の 目的:
- 自発的な頭蓋内出血 (sICH) の後に口服または注射抗凝固剤の治療を再開するための理想的な時間間隔を特定する.
主な方法:
- 2000年6月から2022年5月までの間に治療を受けた90人の患者による遡及コホート研究.
- 抗凝固剤の再投与後の出血および血栓塞栓の分析
- 最適なタイミングの特定のために利用された受信機操作特性 (ROC) と局所的に推定された分散図の平滑化 (LOESS).
主要な成果:
- 患者の平均年齢は71歳であり,63. 3%がワーファリン,22. 2%が非ビタミンK抗凝固剤 (NOAC) を使用した.
- 治療再開後6ヶ月以内に9人の患者で出血,13人の患者で不血症の合併症が発生した.
- 併合合併症のリスクは,脳卒中後20~22日間で抗凝固薬を再開すると見られた.
結論:
- sICH の約3週間後に抗凝固剤を再開することは,併合されたリスクを最小限に抑えるのに最適である可能性があります.
- 年齢と抗凝固剤のタイプ (NOACs) は合併症の危険因子でした.
- 臨床的決定には,これらの発見とともに個別的な評価が必要です.
関連する概念動画
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
Aneurysm IV: Nursing Management
20
Vigilant monitoring for aneurysm rupture is essential for patients undergoing aortic surgery.Preoperative Nursing ManagementContinuously monitor the patient for manifestations of aneurysm rupture, such as pallor, weakness, tachycardia, hypotension, abdominal, back, groin, or periumbilical pain, changes in consciousness, and a pulsating abdominal mass. Regularly assess the patient's peripheral pulses.Instruct the patient to consume a clear liquid diet the day before surgery and administer...
20

